mk-8521
Peptideexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT02055547)
Timeline
Indications
Mechanism of action
GLP1R agonist
- Glucagon receptorAGONIST
GCGR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mk-8521
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02492763 | Phase 2 | Jul 27, 2015 | Merck |
| NCT01982630 | Phase 1 | Nov 1, 2013 | Merck |
| NCT02055547 | Phase 1 | May 1, 2013 | Merck |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 3 | 3 | 2 | 2013 |
1 organizations
Page 1 / 1